| 4.17 -0.19 (-4.36%) | 02-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.18  |
1-year : | 7.05 |
| Resists | First : | 5.29 |
Second : | 6.03 |
| Pivot price | 4.81 |
|||
| Supports | First : | 4.07 |
Second : | 3.39 |
| MAs | MA(5) : | 4.35 |
MA(20) : | 4.98 |
| MA(100) : | 4.7  |
MA(250) : | 4.12 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 4.4 |
D(3) : | 5.2 |
| RSI | RSI(14): 27.1 |
|||
| 52-week | High : | 6.17 | Low : | 2.36 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CTKB ] has closed above bottom band by 6.7%. Bollinger Bands are 41.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.4 - 4.42 | 4.42 - 4.44 |
| Low: | 4.01 - 4.04 | 4.04 - 4.07 |
| Close: | 4.12 - 4.17 | 4.17 - 4.21 |
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Thu, 12 Feb 2026
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - GlobeNewswire
Tue, 10 Feb 2026
New York State Common Retirement Fund Has $1.15 Million Holdings in Cytek Biosciences, Inc. $CTKB - MarketBeat
Thu, 05 Feb 2026
Cytek Biosciences, Inc. (NASDAQ:CTKB) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Sun, 01 Feb 2026
This Cytek Biosciences Insider Increased Their Holding By 169% Last Year - Yahoo Finance
Thu, 22 Jan 2026
Cytek Biosciences, Inc. (CTKB) Investor Outlook: Analyzing The 8.70% Potential Upside - DirectorsTalk Interviews
Mon, 19 Jan 2026
Institutional owners may take dramatic actions as Cytek Biosciences, Inc.'s (NASDAQ:CTKB) recent 6.9% drop adds to one-year losses - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 128 (M) |
| Shares Float | 102 (M) |
| Held by Insiders | 9.2 (%) |
| Held by Institutions | 63.8 (%) |
| Shares Short | 6,390 (K) |
| Shares Short P.Month | 6,790 (K) |
| EPS | -0.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.96 |
| Profit Margin | -6.6 % |
| Operating Margin | -17.6 % |
| Return on Assets (ttm) | -4.4 % |
| Return on Equity (ttm) | -3.4 % |
| Qtrly Rev. Growth | 1.5 % |
| Gross Profit (p.s.) | 0.82 |
| Sales Per Share | 1.53 |
| EBITDA (p.s.) | -0.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | 5 (M) |
| PE Ratio | -37.91 |
| PEG Ratio | 0 |
| Price to Book value | 1.4 |
| Price to Sales | 2.7 |
| Price to Cash Flow | -277.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|